Class Action Lawsuit on Behalf of Albany Molecular Research Inc. Investors Announced by Kirby McInerney LLP

Kirby McInerney LLP announced today that a class action lawsuit is pending in the United States District Court for the Eastern District of New York on behalf of investors who acquired Albany Molecular Research Inc. (“Albany” or the “Company”) (Nasdaq:AMRI) securities during the period from August 5, 2014 to November 5, 2014 (the “class period”). Pursuant to applicable law, investors have until January 12, 2015 to file a motion to be appointed as lead plaintiff in the investor lawsuit.

The lawsuit charges that during the class period the Company touted its acquisition of pharmaceutical products manufacturer OsoBio, and raised the Company’s projected diluted earnings per share and contract growth for 2014 in light of the acquisition. However, the Company misled investors by omitting that the OsoBio facility experienced a business interruption in July 2014, which led to the loss of finished product, required remediation of one of its suites, and meaningfully impaired the Company’s outlook for 2014.

On November 5, 2014, the Company issued a press release and filed a Form 8-K with the SEC revealing the interruption. On this news, the price of AMRI fell from $22.67 on November 4, 2015 to $16.59 on November 5, 2014, a loss of value of over 35%.

If you acquired Albany securities during this period and you are interested in learning more about this matter and any rights you might have with respect to these claims, contact Jess Kelley at securitiescases@kmllp.com, by telephone at (212) 371-6600, or by filling out this form. Please bear in mind that some of these rights may be time-sensitive.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, whistleblower, antitrust and consumer litigation. The firm has specialized in complex litigation, including securities class actions, for several decades. Kirby McInerney LLP has repeatedly demonstrated its expertise in this field, and has been recognized by various courts that have appointed the firm to major positions in consolidated and multi-district litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars, and the firm’s achievements and quality of service have been chronicled in numerous published decisions. Additional information about the firm or the claims against Albany can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.

Kirby McInerney LLPJess Kelley, 212-371-6600securitiescases@kmllp.com

Albany Molecular Research, Inc. (NASDAQ:AMRI)
Historical Stock Chart
From Mar 2024 to Apr 2024